Navigation Links
Washington University increases fleet of Roche Genome Sequencer FLX Systems
Date:2/7/2008

INDIANAPOLISThe Genome Sequencing Center at Washington University School of Medicine increased its sequencing capacity with an agreement to acquire five additional Genome Sequencer FLX Systems from Roche Diagnostics.

With a total of eight Genome Sequencer FLX Systems, the Genome Sequencing Center will be able to support a wide variety of projects with the 454 Sequencing technology, ranging from the sequencing of new complex genomes to the diverse microbial world to the resequencing of portions of the human genome to identify genetic variations that may be associated with human diseases. This will include using the instruments for transcriptome analysis of individual tumors, an approach that the Genome Sequencing Center has pioneered as part of its ongoing studies of acute myeloid leukemia.

We have been able to complete several projects with the GS FLX, demonstrating the systems strengths, said Richard Wilson, Director of the Genome Sequencing Center at Washington University School of Medicine. We now believe that with the new improvements and the increased throughput of the instrument, we will be able to complete several projects more quickly than originally anticipated and at a substantially lower cost.

We are continuing to see the GS FLX moved into production settings due to the instruments scalability and reliability, which allows it to run continuously, said Lonnie Shoff, Senior Vice President of Applied Science for Roche Diagnostics. With more than 140 peer reviewed publications, we have a proven technology that continues to reshape the life sciences market.

In addition to the purchase agreement, the Genome Sequencing Center and Roche announced the Centers participation in the early access program for new technology advancements for the Genome Sequencer FLX system. The early access program will be featured Friday, Feb. 8 at the Advances in Genome Biology and Technology Conference in Marco Island, Florida.

T
'/>"/>

Contact: Lori McLaughlin
lori.mclaughlin@roche.com
317-521-3112
Roche Diagnostics
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Missouri board grants Washington University Sustainability Center $3 million
2. Washington University, 2 industries, team to clean up mercury emissions
3. DHS Begins Collecting 10 Fingerprints From International Visitors at Washington Dulles International Airport
4. First IEEE-USA Innovation Forum coming to Washington area in November
5. Core blimey! University of Leicester scientist calls for geological time machine
6. University of Chicago launches research program in catastrophic deformation
7. GM, Coskata partnership builds on Oklahoma State University biofuels research
8. Mongolian paleontologists with a dream come to Montana State University
9. Montana State University researcher finds renewed interest in turning algae into fuel
10. University of Alberta researchers report breakthrough in lowering bad cholesterol, fatty acid levels
11. Five young Hebrew University scientists win first competitive EU grants

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...e course of a lifetime, the heart pumps some 250 m...der to do this, the muscle fibers of the heart hav...ed by Dr. Wolfgang Rottbauer, vice chair of the De...Hospital (Chairman: Prof. Dr. H. A. Katus), has di...bility of the smallest muscular unit, the sarcomer...
(Date:11/24/2009)...us Research Institute (LRI) today named 12 new gra...million, recognize innovative work across a broad ...their creativity, novelty, and potential to drive ... and cure the complex disease of systemic lupus. ,...lupus researchers across the nation and include in...
(Date:11/24/2009)...mic-level action of a remarkable class of ring-sha...rs with the Lawrence Berkeley National Laboratory ...ystallography beamline at the Advanced Light Sourc...n gene expression and replication, and are vital t... infectious agents, such as the human papillomavir...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4NIMBioS hosts tutorial on optimal control and optimization for biologists 10071 1New Parkinsons Drug Draws Mixed Reviews 58192 1New Parkinsons Drug Draws Mixed Reviews 58192 2New Parkinsons Drug Draws Mixed Reviews 58192 3Minorities Less Likely to Have Blood Pressure Under Control 58190 1Minorities Less Likely to Have Blood Pressure Under Control 58190 2Minorities Less Likely to Have Blood Pressure Under Control 58190 3
..., , Svilen Bobev, assistant professor of chemistry...ce Foundation,s prestigious Faculty Early Career D...g award, designed to support the integrated resear...their careers, is bestowed on those scientists and...ic leaders of the 21st century. Fewer than 20 perc...
..., Researchers from the University of North Caroli...mechanism that may account for the development of ...e born with in the US every year. The findings, p...oS Computational Biology, add new knowledge to und... also point the way to new corrective treatments. ...
..., NEW YORK (Feb. 28, 2007) -- The general public ...ase (CKD) is a serious and progressive medical con...ed. Understandably so, since in its early stages C...the disease and their health-care providers unawar...r, if CKD is detected and treated early, its wides...
Other Biology News:UD's Bobev receives NSF Early Career Award for research on novel compounds of rare Earth metals 2UD's Bobev receives NSF Early Career Award for research on novel compounds of rare Earth metals 3Computer simulations point to key molecular basis of cystic fibrosis 2Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines 2Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines 3Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines 4
(Date:11/24/2009)... , REYKJAVIK, Iceland, Novembe...c. (Nasdaq: DCGN ) today announced the approval of...ptcy Court for the District of Delaware,(the "Bank... petition for,relief under Chapter 11 of the Unite.... , The orders issued by the Bankruptcy C...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia/...ood & Drug Administration (SFDA) has approved ... its oral insulin project,(Nodlin), an innovative ...proval allows Biolaxy to initiate its first phase ...r characteristic of high blood glucose and poor,me...
(Date:11/24/2009)... , , Primary efficacy endpoint has been met... endometrial cancer, , QUEBEC CITY, Nov. 24 /...DAQ: AEZS ; TSX: AEZ) (the "Company"), a global b...apy and oncology, today announced positive efficac...toxic peptide conjugate, AEZS-108 (formerly AN-152...
(Date:11/24/2009)... , SAN DIEGO, Nov. 24, 2009 /PRNewswire-Fir...RNA ) announced today that the company is schedu...alth Care Conference on December 1, 2009 at 11:30 ...New York Palace Hotel in New York City. Jack Lief,... scheduled to provide an overview of the company, ...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
... Integrated Global Services, CAMBRIDGE, Mass., Ap...launches under a new name, Abt Bio-Pharma Solution...es Inc. The company will continue to,provide custo...for the,pharmaceutical, biotechnology, medical dev...proach that blends decades of experience with wide...
...08 Cardium Therapeutics,(Amex: CXM ) and its ope...at,InnerCool has entered into a European commercia...Euromed), a leading distributor of cardiology,medi...romed will have,exclusive marketing, sales and dis...nd for InnerCool,s portfolio of temperature modula...
... 1, 2008 Derma Sciences,Inc (OTC Bulletin Board: ...reported that sales for 2007 were $34.1 million, a...ported for 2006. Gross margins held steady at 34,p... in new products for the,pipeline, and expanding t...ny reported a loss of $2.3 million or $0.09 loss p...
Other Biology Technology:Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 6Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 7Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 8Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 9Derma Sciences Reports Fourth Quarter Year-End Results for 2007 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 3Derma Sciences Reports Fourth Quarter Year-End Results for 2007 4Derma Sciences Reports Fourth Quarter Year-End Results for 2007 5
T4 Polynucleotide Kinase Exchange Reaction Buffer from Invitrogen
IMAGEQUANT 400 IQTL from GE Healthcare, formerly Amersham Biosciences
IMAGEQUANT 100 WKSTN from GE Healthcare, formerly Amersham Biosciences
FlowTACS Flow Cytometry Apoptosis Detection Kit from R&D Systems
Biology Products: